Cargando…
Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with...
Autores principales: | Hotta, Takamasa, Okimoto, Tamio, Hamaguchi, Megumi, Tsubata, Yukari, Isobe, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008039/ https://www.ncbi.nlm.nih.gov/pubmed/31534079 http://dx.doi.org/10.2169/internalmedicine.2597-18 |
Ejemplares similares
-
Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018) -
A Low Crizotinib Concentration in the Cerebrospinal Fluid Causes Ineffective Treatment of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer with Carcinomatous Meningitis
por: Okimoto, Tamio, et al.
Publicado: (2018) -
Comparative Analysis of the Attitudes toward Palliative Care between Medical Oncologists and Pulmonologists
por: Okimoto, Tamio, et al.
Publicado: (2021) -
Exogenous lipoid pneumonia caused by herbicide inhalation
por: Hotta, Takamasa, et al.
Publicado: (2016) -
Pleuroparenchymal fibroelastosis after haematopoietic stem cell transplantation without graft‐versus‐host disease findings
por: Okimoto, Tamio, et al.
Publicado: (2018)